GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
March 28 2024 - 9:00AM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a
biotechnology company advancing an innovative pipeline of Natural
Killer T (NKT) cell modulators for the treatment of inflammatory,
fibrotic and autoimmune diseases, today announced that Marc Hertz,
PhD, Chief Executive Officer of GRI Bio, will present at the
MedInvest Biotech & Pharma Investor Conference being held in
New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.
In addition to the presentation, management will
be available to participate in one-on-one meetings with qualified
members of the investor community who are registered to attend the
conference. For more information about the conference, please visit
the conference website.
A live webcast of the event will be available on
the Events page of the Investors section of the Company’s website
(www.gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. iNKT cells play a critical role in
propagating the injury, inflammatory response, and fibrosis
observed in inflammatory and fibrotic indications. GRI Bio’s lead
program, GRI-0621, is an inhibitor of iNKT cell activity and is
being developed as a novel oral therapeutic for the treatment of
IPF, a serious disease with significant unmet need. The Company is
also developing a pipeline of novel type 2 NKT agonists for the
treatment of SLE. Additionally, with a library of over 500
proprietary compounds, GRI Bio has the ability to fuel a growing
pipeline.
Investor Contact:JTC Team, LLCJenene
Thomas(833) 475-8247GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
GRI Bio (NASDAQ:GRI)
Historical Stock Chart
From Sep 2023 to Sep 2024